Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Trial Profile

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs SCY 078 (Primary)
  • Indications Candidiasis
  • Focus Expanded access; Therapeutic Use
  • Acronyms FURI
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 07 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 13 Mar 2017 According to a Scynexis media release, expected enrollment for patients in this study to commence in the first half of 2017.
    • 02 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top